Clinical Trials - CLSD

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT05891548Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular DegenerationCOMPLETEDPHASE22023-05-312024-08-202024-08-20
NCT04626128Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMDCOMPLETEDPHASE1, PHASE22020-12-152022-10-132022-10-13
NCT03203447Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVOTERMINATEDPHASE32018-03-052018-12-182018-12-18
NCT03126786Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular EdemaCOMPLETEDPHASE22017-07-112018-04-172018-04-17
NCT03097315Suprachoroidal Injection of CLS-TA in Patients With Non-infectious UveitisCOMPLETEDPHASE32017-04-042018-01-242018-01-24
NCT02980874Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVOTERMINATEDPHASE32017-01-312018-12-102018-12-10
NCT02949024Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular EdemaCOMPLETEDPHASE1, PHASE22016-11-102017-10-172017-10-17
NCT02595398Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious UveitisCOMPLETEDPHASE32015-11-172018-01-182018-01-18
NCT02303184Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVOCOMPLETEDPHASE22015-012016-032016-03
NCT02255032Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious UveitisCOMPLETEDPHASE22014-102016-012015-12
NCT01789320Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat UveitisCOMPLETEDPHASE1, PHASE22013-022015-032015-03